Literature DB >> 2688325

Ofloxacin: a review.

M A Smythe1, M J Rybak.   

Abstract

Ofloxacin is a new fluorinated quinolone antibiotic with a broad spectrum of activity against a variety of gram-positive and -negative bacteria including Enterobacteriaceae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. In addition, ofloxacin has significant activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycobacterium tuberculosis and this may give rise to new indications for the class of quinolone antibiotics. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Significant drug interactions with ofloxacin have not been reported.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688325     DOI: 10.1177/106002808902301101

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  4 in total

Review 1.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

2.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

3.  Modified Fluoroquinolones as Antimicrobial Compounds Targeting Chlamydia trachomatis.

Authors:  Thi Huyen Vu; Erika Adhel; Katarina Vielfort; Ngûyet-Thanh Ha Duong; Guillaume Anquetin; Katy Jeannot; Philippe Verbeke; Sofia Hjalmar; Åsa Gylfe; Nawal Serradji
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 4.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.